SimpleAdvanced       Search Search 151 Open Trials. Phone:(877.827.8839)
Protocol No. Title Status
2014-1503 Use of Portable Diffuse Optical Spectroscopy Technologies for Non-Invasive Hemodynamic Evaluation of Trauma/Critically Care Patients Open
2015-2059 A Prospective, Multicenter, Open-Label, Single-Arm Study of the Safety and Tolerability of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects with Retinitis Pigmentosa (RP) Open
2015-2390 A Double-Blind, Controlled Phase 2 Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients with Chronic Motor Deficit from Traumatic Brain Injury (TBI) Open
2015-2391 A Double-Blind, Controlled Phase 2B Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients with Chronic Motor Deficit from Ischemic Stroke Open
2016-2778 A Phase IIA, Multi-Center, Randomized, Single-Blind, Placebo-Controlled, Crossover Study To Assess The Safety, Tolerability, And Preliminary Efficacy Of A Single Intravenous Dose of Allogeneic Human Mesenchymal Stem Cells To Subjects With Mild to Moderate Dementia Due to Alzheimer's Disease (Protocol: STEM105-M-AD Date: May 21, 2015) Open
2016-2972 PLEGRIDY® (peginterferon ß 1a) Real World effectiveness and Safety Observational Program POP Open
2016-2975 The Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study will establish an open-label, longitudinal cohort study to assess the impact of amyloid PET on patient outcomes. Open
2016-3135 An Assessment of Humacyte's Human Acellular Vessel in Patients Needing Renal Replacement Therapy: A Comparison with ePTFE Grafts as Conduits for Hemodialysis (HUMANITY) Open
2016-3241 An Extension Study of JC-01 Evaluating Long-Term Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects with Retinitis Pigmentosa (RP) Open
2017-3605 WIRB Reliance #29: A Randomized, Double-Blind, Active Comparator-Controlled, Crossover Study to Assess the Capacity of Delayed-Release Prednisone (RAYOS®) Compared to Immediate-Release Prednisone to Improve Fatigue and Control Morning Symptoms in Subjects with Generalized Systemic Lupus Erythematosus Open
2017-3643 Randomized, Double blind, Active Control Study of the Safety and Efficacy of PRX-102 compared to Agalsidase Beta on Renal Function in Patients with Fabry Disease Previously Treated With Agalsidase Beta Open
2017-3807 A Phase 3 Study to Compare the Efficacy and Safety of Humacyte’s Human Acellular Vessel with that of an Autologous Arteriovenous Fistula in Subjects with End-Stage Renal Disease Open
2017-3818 A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF REPEATED ADMINISTRATIONS OF NUROWN® (AUTOLOGOUS MESENCHYMAL STEM CELLS SECRETING NEUROTROPHIC FACTORS) IN PARTICIPANTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) Open
245685 Boeing Takes Off: Employee Weight Loss Program Open
ALLIANCE-A011502 (CIRB) A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial Open
ALLIANCE-A021501 Preoperative Extended Chemotherapy Vs. Chemotherapy Plus Hypofractionated Radiation Therapy For Borderline Resectable Adenocarcinoma Of The Head Of The Pancreas Open
ALLIANCE-A071401 Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2 Mutations Open
ALLIANCE-A221101 A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients with High Grade Glioma Open
CHOC-392MD/44/C An Open-label, cross-over, pharmacokinetic study to assess the safety and pharmacokinetics of transdermal granisetron (Sancuso patch) and IV granisetron in a pediatric oncology population (aged 13 to 17 years). Open
CHOC-AAML1031 AAML1031, A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND#69896, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD Open
CHOC-CPT-SIOP-2009 CPT-SIOP-2009, Intercontinental Multidisciplinary Registry and Treatment Optimization study for Patients with Choroid Plexus Tumors Open
ECOG-E1910 (CIRB) A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults Open
ECOG-E1A11 (CIRB) Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE) Open
ECOG-EAF151 (CIRB) Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma Open
ECOG-EAY131 (CIRB) Molecular Analysis for Therapy Choice (MATCH) Open
GOG-0237 Comparative Analysis Of CA-IX, p16, Proliferative Markers And Human Papilloma Virus (HPV) In The Diagnosis Of Significant Cervical Lesions In Patients With A Cytologic Diagnosis Of Atypical Glandular Cells (AGC) Open
GOG-0263 (CIRB) Randomized Phase III Clinical Trial Of Adjuvant Radiation Versus Chemoradiation In Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy And Pelvic Lymphadenectomy Open
GOG-0278 Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy With Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (=/<2CM) Cervical Cancer Open
GOG-0279 A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent With Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva Open
GOG-0286B (CIRB) A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer Open
GOG-0724 (CIRB) Phase III Randomized Study Of Concurrent Chemotherapy And Pelvic Radiation Therapy With Or Without Adjuvant Chemotherapy In High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy Open
GOG-3009 Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV Open
NRG-BN001 (CIRB) Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Open
NRG-BN003 (CIRB) Phase III trial of observation versus irradiation for a gross totally resected grade II meningioma Open
NRG-BR002 (CIRB) A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer Open
NSABP-B-51 (CIRB) A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy Open
RTOG-0848 (CIRB) A Phase II-R and A Phase III Trial Evaluating Both Erlotinib (PH II-R) and Chemoradiation (PH III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma Open
RTOG-0920 (CIRB) A Phase III Study of Postoperative Radiation Therapy (IMRT) +/-Cetuximab for Locally-Advanced Resected Head and Neck Cancer Open
RTOG-3503 Phase II Trial of Optune Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma Open
SWOG-N1048 (CIRB) A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision Open
SWOG-S0820 A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III (Paces) Open
SWOG-S1207 (CIRB) Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer Open
SWOG-S1418 (CIRB) A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy Open
SWOG-S1609 (CIRB) DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Open
UCI-01-61 A Humanitarian Device Exemption Use Protocol of TheraSphere® HUD For Treatment of Unresectable Primary or Secondary Liver Cancer Open
UCI-03-03 Immunologic Factors Affecting Outcomes in Patients with Liver Cancer Open
UCI-06-13 Evaluation of Predictive Signatures of Prostate Cancer Open
UCI-07-40 Phase I Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, a C-MET/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer (Appendix T) Open
UCI-08-51 Near Infrared Optical Coherence Tomography of the Upper Aero-digestive Tract Open
UCI-09-17 Biology of Human Melanocytes and Keratinocytes Open
UCI-10-24 ATHENA Breast Health Network Open
UCI-10-39 Predicting pathological response within the first week of neoadjuvant chemotherapy using functional parameters measured with Diffuse Optical Spectroscopic Imaging (DOSI) Open
UCI-11-16 [DATABASE REVIEW] Data Linkage Study of Ship Yard Workers to Monitor Health Outcomes Open
UCI-11-19 Evaluation of Peritumoral Renal Adipose Tissue to Renal Cancer Aggressiveness Open
UCI-11-30 Skin Imaging with Technologies in Development Open
UCI-12-10 Development of a Quantitative Tissue Optical Index of Breast Density for Prediction of Hormone Therapy Response Open
UCI-12-18 (BIOREPOSITORY PROTOCOL) Comprehensive, Coordinated Clinical, Imaging and Histological Database for the Study of Neurological Outcomes of Cancer and Cancer Treatments Open
UCI-12-40 Atlas Colorectal Health Network Open
UCI-13-02 Assessing Fitness, Physical Activity and Leukocyte Genomic Response to Exercise in Acute Lymphoblastic Leukemia (ALL) Patients in Remission Open
UCI-13-09 Molecular Analysis of Alterations of the PI3K/AKT/mTOR Pathway in Lynch Syndrome-Associated Endometrial Cancer with Clinicopathologic Correlation Open
UCI-13-14 A Randomized, Double-blinded, Placebo-controlled Phase 2 study of (ERC1671/ GM-CSF / Cyclophosphamide) + Bevacizumab vs. (Placebo Injection / Placebo pill) + Bevacizumab in the treatment of recurrent/progressive, Bevacizumab naïve glioblastoma multiforme and gliosarcoma patients (WHO grade IV malignant gliomas) Open
UCI-13-49 Open-Label Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Daily Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies Open
UCI-14-03 Role of inflammation in the pathogenesis of myeloproliferative neoplasm Open
UCI-14-05 Multicenter Diagnostic Imaging Study for the Melanoma Advanced Imaging Dermatoscope (mAID) Open
UCI-14-25 Plasma Exosome Concentration in Cancer Patients Undergoing Treatment Open
UCI-14-30 Low Residue Diet versus Clear Liquid Diet with Split dose PEG-ELS for Colon Cleansing Prior to Colonoscopy, a randomized trial Open
UCI-14-41 Genomic, Epigenomic and Psychosocial Characteristics of Long-Term Survivors of Ovarian Cancer Open
UCI-14-49 Mapping Breast Cancer Survivorship and the Survivor Institutional Interface Open
UCI-14-62 Breast Tumor Oxygenation During Exercise Open
UCI-14-65 Phase II Randomized, Placebo-Controlled Trial of PROSTVAC (PSA-TRICOM) in Patients with Clinically Localized Prostate Cancer Undergoing Active Surveillance Open
UCI-14-67 A Phase II Study of Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel with Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting Open
UCI-14-81 Mi Salud, Mi Vida: A Self-Discovery Tool for Latina Breast Cancer Survivors Open
UCI-14-85 Improving Diagnosis of Breast Cancer by Using a Combined MRI and Positron Emission Mammography (MRI-PEM) System Open
UCI-14-86 Predicting Neoadjuvant Chemotherapy Response by Using a Combined MRI and Scinti-Mammography (MRI-SMM) System Open
UCI-14-89 [BIOREPOSITORY] Hematologic Malignancies Biorepository for human research Open
UCI-14-90 Biomarkers and Clinical Parameters Associated with Gleason Score Upgrading Open
UCI-14-93 UCReliance#1415_Phase 1b Trial of the Combination of Ibrutinib and Azacitidine for the Treatment of Higher Risk Myelodysplastic Syndromes in Previously Treated Patients or in Untreated Patients Unfit for or Who Refuse Intense Therapy Open
UCI-14-96 UCReliance#1265: A Phase I/II Study of PiC-D (Ixazomib in Combination with Pomalidomide, Clarithromycin and Dexamethasone) in Patients with Double Refractory Multiple Myeloma Open
UCI-15-18 An Open-Label, Multi-Center Phase 1 Study to Investigate the Safety and Tolerability of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy Open
UCI-15-22 Electro-Phage and Colorimetric Aptamer Sensors for Clinical Staging and Monitoring of Bladder Cancer Open
UCI-15-31 A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer Open
UCI-15-52 A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy Open
UCI-15-69 A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Open
UCI-15-70 Small Nucleolar RNAs (snoRNAs) And Alternative Splicing In Castration-Resistant Prostate Cancer: A Potential Role In Regulation Of Androgen Receptor Signaling Open
UCI-15-74 An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements Open
UCI-15-77 A Phase II Clinical Trial to study the efficacy and safety of pembrolizumab (MK-3475) in subjects with high risk non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG) therapy Open
UCI-15-78 An Open-Label, Phase I/II, Dose-Escalation Study Evaluating The Safety And Tolerability of GDC-0032 In Patients With Locally Advanced Or Metastatic Solid Tumors Or Non-Hodgkin's Lymphoma And In Combination With Endocrine Therapy In Patients With Locally Advanced Or Metastatic Hormone Receptor-Positive Breast Cancer Open
UCI-15-79 Phase II Open-Label Randomized Study of Radiosurgery with or without Tumor Treating Fields (TT Fields) for 1-10 Brain Metastases from Non-Small Cell Lung Cancer (NSCLC) Open
UCI-15-80 A Phase 3 Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF /Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy Open
UCI-15-81 Phase 1 Dose-Escalating Study of Combining Intravenous Tirapazamine and Transarterial Embolization (TAE) in Hepatocellular Carcinoma Open
UCI-15-82 A phase II, multicenter, study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC) Open
UCI-15-83 Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging in a Multi-Center Setting Open
UCI-15-94 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus nab-Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma Open
UCI-15-96 A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177). Open
UCI-15-99 Open-label, non-randomized, phase 2 study evaluating efficacy and safety of PQR309 in patients with relapsed or refractory primary CNS lymphoma Open
UCI-16-01 Pathway Analyses for Individualized Network Therapeutics for Cancer (PAINT Cancer) Open
UCI-16-02 Breast and Cervical Cancer Survivorship in Zambia: Quality of Life, Social Support, and the Role of HIV/AIDS Open
UCI-16-10 A Phase 1b/2 Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (GS-9973) with Vincristine and Dexamethasone in Adult Subjects with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) Open
UCI-16-100 A Phase 2/3 Multicenter, Open-label, 3-arm, 2-Stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia With FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy Open
UCI-16-19 ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy Open
UCI-16-23 Enabling a Paradigm Shift: A Preference-Tolerant RCT of Personalized vs. Annual Screening for Breast Cancer [The WISDOM Study (Women Informed to Screen Depending On Measures of Risk)] Open
UCI-16-25 A Randomized, Open-Label, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) In Combination with and/or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer (Javelin Ovarian 100) Open
UCI-16-31 [EXEMPT - RETROSPECTIVE] Importin &#945; is a Novel Biomarker of Barrett's Esophagus (BE)-Related Dysplasia & Cancer and Promotes Growth of BE-Derived Cancer Cells by Inducing Aberrant VEGF Expression Open
UCI-16-40 An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma Open
UCI-16-43 Prospective Collection of Human Colon Cancer Tissue Samples For Development of Patient Derived Xenograft Mouse Models and 3D-Vascularized Microtumor Chambers Open
UCI-16-45 A Phase I/Ib, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a dual PI3K delta/gamma inhibitor, in Patients with Relapsed or Refractory T-cell Lymphoma Open
UCI-16-46 A Phase 1 dose-ranging study to investigate the safety, tolerability and pharmacokinetics of MRG-106 following local intratumoral, subcutaneous, and intravenous administration in subjects with various lymphomas and leukemias Open
UCI-16-50 A Phase 1b/2, Open-Label, Multicentre Study Assessing the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Open
UCI-16-52 A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation Open
UCI-16-53 FOCUS: A Multicenter, Multinational, Double-blind, 2-Arm, Randomized, Phase 2/3, Study of Physician's Choice Chemotherapy (PCC) (Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects with Platinum-Resistant, Recurrent, Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Open
UCI-16-54 Identification of functional MRI, neuropsychiatric, and circulating VEGF changes after marizomib treatment in patients enrolled in the UCI 14-58 study (single agent marizomib cohort) Open
UCI-16-55 Phase 1b, Multicenter, Open-Label Study of Marizomib with Temozolomide and Radiotherapy in Patients with Newly Diagnosed WHO Grade IV Malignant Glioma Open
UCI-16-57 Phase-I trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas Open
UCI-16-63 A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-426) Open
UCI-16-65 A Phase 1 clinical trial to evaluate obinutuzumab with high-dose ibrutinib for the treatment of patients with chronic lymphocytic leukemia with progressive disease on single agent ibrutinib Open
UCI-16-69 ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed, BRCA-Mutant, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Open
UCI-16-70 Evaluation of Mitochondrial Priming in T Cell Lymphomas Open
UCI-16-71 A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors Open
UCI-16-72 A Randomized Double-Blind Phase 3 Study Of Avelumab In Combination With Standard Of Care Chemoradiotherapy (Cisplatin Plus Definitive Radiation Therapy) Versus Standard Of Care Chemoradiotherapy In The Front-Line Treatment Of Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck Open
UCI-16-74 A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician's Choice (TPC) in Patients with Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated with an Anthracycline, a Taxane, and Capecitabine Open
UCI-16-76 Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365) Open
UCI-16-77 Identification of Features Associated with Dysplasia Using the NvisionVLE® Imaging System Pilot Trial Open
UCI-16-79 A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) Open
UCI-16-82 DecisionDx-Melanoma 31-Gene Expression Profile Clinical Impact Study #4 Open
UCI-16-84 A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Of Atezolizumab (Anti-PD-L1 Antibody) As Adjuvant Therapy In Patients With Renal Cell Carcinoma At High Risk Of Developing Metastasis Following Nephrectomy Open
UCI-16-88 Development of Esophageal and Gastric Cancer Patient Derived Xenograft Mouse Models to Investigate Chemotherapy Resistance and Tumor Cell Response Open
UCI-16-90 A Phase III, Multicenter, Randomized Study Of Atezolizumab (Anti-PD-L1 Antibody) In Combination With Enzalutamide Versus Enzalutamide Alone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of An Androgen Synthesis Inhibitor And Failure Of, Ineligibility For, Or Refusal Of A Taxane Regimen Open
UCI-16-92 [WIRB] A Phase III, Double-Blinded, Randomized, Placebo-Controlled Study of Atezolizumab Plus Cobimetinib and Vemurafenib versus Placebo plus Cobimetinib and Vemurafenib in Previously Untreated BRAF V600 Mutation-Positive Patients with Metastatic or Unresectable Locally Advanced Melanoma Open
UCI-16-94 Phase IIA Single-Arm Study of Treatment of Patients with Advanced Liver Cancer with a Combination of TATE (Transarterial Tirapazamine Embolization) Followed by an Anti- PD-1 Monoclonal Antibody Open
UCI-16-95 A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of a Non-Covalent, Reversible Bruton's Tyrosine Kinase Inhibitor, SNS 062, in Patients With B-Lymphoid Malignancies Open
UCI-16-96 A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors Open
UCI-16-99 Coldplay 3: Multi-Center Clinical Study to Evaluate the C2 CryoBalloon™ Focal Ablation System for the Treatment of Patients with Previously-Untreated Dysplastic Barrett's Epithelium Open
UCI-17-03 Phase 2 Study of the Combination of Ibrutinib Plus Venetoclax in Subjects with Treatment Naïve Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Open
UCI-17-04 Evaluation of Virtual Reality Renal Models as Educational and Preoperative Planning Tools for Partial Nephrectomy: A Pilot Study Open
UCI-17-05 Understanding Intratumoral Heterogeneity Using Single Cell RNA Sequencing Open
UCI-17-07 Patient Reported Outcomes via Online Questionnaire (PROVOQ): Post-Radical Prostatectomy Outcome Assessment Open
UCI-17-08 Peripheral Hormonal Profile in Women with Breast Lesions Open
UCI-17-09 A Randomized, Double-Blind, Placebo-Controlled, Phase III Study Comparing the Combination of PDR001, Dabrafenib and Trametinib versus Placebo, Dabrafenib and Trametinib in Previously Untreated Patients with Unresectable or Metastatic BRAF V600 Mutant Melanoma Open
UCI-17-10 A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib plus Abiraterone plus Prednisone/Prednisolone, Relative to Placebo plus Abiraterone plus Prednisone/Prednisolone in Adult Male Patients with Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer Open
UCI-17-12 Optimization of Magnetic Resonance Imaging Applications on the 1.5 and 3.0 Tesla for Cardiovascular and Pulmonary Systems Open
UCI-17-13 Vigilant ObservatIon of GlIadeL WAfer ImplaNT (VIGILANT) Registry: A Multicenter, Observational Registry to Collect Information on the Safety and Effectiveness of Gliadel® Wafer (Carmustine Implant) Used in Usual Medical Practice Open
UCI-17-15 The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms Trial): Focus Groups to Refine a Nutritional Intervention Open
UCI-17-19 A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 in Subjects with Relapsed or Refractory Haematologic Malignancies Open
UCI-17-22 Epigenetic markers for pesticide exposure and cancer risk Open
UCI-17-31 An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis Open
UCI-17-33 A Randomized Phase 2 Trial of Neoadjuvant and Adjuvant Therapy with the IRX-2 Regimen in Patients with Newly Diagnosed Stage II, III or IVA Squamous Cell Carcinoma of the Oral Cavity. Open
UCI-17-40 Precision Medicine for Early Prostate Cancer: Integrating Biological and Patient Complexity Variables to Predict Treatment Response Open
UCI-17-45 COMPLEEMENT-1: An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease Open
UCI-17-91 [EXEMPTED] Compassionate Use study of ICT-107 with maintenance temozolomide (TMZ) in newly diagnosed glioblastoma following resection and concomitant TMZ chemotherapy Open
UCI-95-29 Measurement of Breast Tissue Optical Properties Open
UCI-98-41 Outcomes and Assessment of Prostate Cancer at UCIMC Open